TNDM:NSD-Tandem Diabetes Care Inc. (USD)

EQUITY | Medical Devices | NASDAQ Global Market

Last Closing

USD 51.73

Change

0.00 (0.00)%

Market Cap

USD 0.07B

Volume

1.04M

Analyst Target

USD 120.13
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Tandem Diabetes Care Inc is a medical device company engaged in the designing, development and commercialization of products for people with insulin-dependent diabetes. The Company's flagship product is the t:slim Insulin Delivery System.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-26 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

N/A

USD 46.05B
ALGN Align Technology Inc

N/A

USD 19.27B
PODD Insulet Corporation

N/A

USD 13.41B
SWAV Shockwave Medical Inc

N/A

USD 12.57B
BRKR Bruker Corporation

N/A

USD 9.79B
MASI Masimo Corporation

N/A

USD 6.66B
TMDX TransMedics Group Inc

N/A

USD 4.52B
PRCT Procept Biorobotics Corp

N/A

USD 3.54B
AXNX Axonics Modulation Technologie..

N/A

USD 3.43B
IRTC iRhythm Technologies Inc

N/A

USD 3.02B

ETFs Containing TNDM

DDOC:XETRA Global X Telemedicine & D.. 4.98 % 0.00 %

N/A

USD 5.39M
DDOC:F Global X Telemedicine & D.. 4.98 % 0.00 %

N/A

USD 4.76M
EDOC:SW Global X Telemedicine & D.. 4.98 % 0.00 %

N/A

USD 4.69M
EDOG:LSE Global X Telemedicine & D.. 4.48 % 0.00 %

N/A

USD 0.15M
EDOC:LSE Global X Telemedicine & D.. 4.33 % 0.00 %

N/A

USD 4.72M
CYBG:LSE VanEck Bionic Engineering.. 4.05 % 0.00 %

N/A

USD 6.34M
CIB0:XETRA VanEck Bionic Engineering.. 4.00 % 0.00 %

N/A

USD 6.26M
FDHT 3.22 % 0.00 %

N/A

N/A
PSCH Invesco S&P SmallCap Heal.. 2.84 % 0.29 %

N/A

USD 0.20B
XHE SPDR® S&P Health Care Eq.. 2.73 % 0.35 %

N/A

USD 0.26B
QQQS Invesco NASDAQ Future Gen.. 1.03 % 0.00 %

N/A

USD 8.10M
SLIM 0.00 % 0.50 %

N/A

N/A
SSLY Syntax Stratified SmallCa.. 0.00 % 0.00 %

N/A

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 74.88% 90% A- 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 74.88% 90% A- 94% A
Trailing 12 Months  
Capital Gain 94.69% 93% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 94.69% 93% A 94% A
Trailing 5 Years  
Capital Gain -21.13% 67% D+ 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -21.13% 67% D+ 35% F
Average Annual (5 Year Horizon)  
Capital Gain -5.50% 38% F 32% F
Dividend Return -5.50% 38% F 30% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 57.67% 51% F 28% F
Risk Adjusted Return -9.54% 40% F 35% F
Market Capitalization 0.07B 91% A- 85% B

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 495.13 3% 2%
Price/Book Ratio 6.90 25% 16%
Price / Cash Flow Ratio -105.04 98% 97%
Price/Free Cash Flow Ratio -10.72 85% 85%
Management Effectiveness  
Return on Equity -48.63% 57% 32%
Return on Invested Capital -35.65% 50% 27%
Return on Assets -9.70% 68% 34%
Debt to Equity Ratio 90.88% 34% 25%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.